Low-dose intravenous ondansetron (8 mg) plus dexamethasone: An effective regimen for the control of carboplatin-induced emesis

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 4, 1997, Pages 224-226

  Markman, Maurie ^a   Kennedy, Alexander ^a   Webster, Kenneth ^a   Peterson, Gertrude ^a   Kulp, Barbara ^a   Belinson, Jerome ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

carboplatin induced emesis; dexamethasone; ondansetron

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; DEXAMETHASONE; ONDANSETRON; PACLITAXEL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0030925495     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01240319     Document Type: Article

References (15)

1. Alberts DA, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706-717
2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MM, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140-147
3. Chapman SM, Pruemer JM (1993) Ondansetron use in a major university teaching hospital. Am J Hosp Pharm 50: 670-674
4. DeMulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, crossover study. Ann Intern Med 133: 834-840
5. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329: 1790-1796
6. Harvey VJ, Evans BD, Mitchell PLR, Mak D, Neave LM, Langley GB, Dickson DSP (1991) Reduction of carboplatin induced emesis by ondansetron. Br J Cancer 63: 942-944
7. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B, Plagge P, Flack NE (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12: 596-600
8. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1996) Control of carboplatin-induced emesis with a fixed low-dose of granisetron (0.5 mg) plus dexamethasone Gynecol Oncol 60: 435-437
9. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega JM (1990) The natural course of emesis after carboplatin treatment. Acta Oncologica 29: 593-595
10. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D, on behalf of the Granisetron Study Group (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13: 1242-1248
11. Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13: 1036-1043
12. Peters II MD, Long KS, Patel HS, Reitz JA, Jessen LM, Emhart GC (1993) Multicenter evaluation of ondansetron use in hospitalized oncology patients. Am J Hosp Pharm 50: 1164-1170
13. Rose WC, Schurig JE (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev. 12 (suppl A): 1-19
14. Smyth JH, Coleman RE, Nicolson M, Gallmeier WM, Leonard RCF, Cornbleet MA, Allan SG, Upadhyaya BK, Bruntsch U (1991) Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 303: 1423-1426
15. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B, Pater J (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randormized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10: 718-726